GLAUKOS CORP(NYSE:GKOS) stock Fundamental Analysis

Fundamental Rating

GKOS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. While GKOS seems to be doing ok healthwise, there are quite some concerns on its profitability. GKOS shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

GKOS had negative earnings in the past year.

In the past year GKOS has reported a negative cash flow from operations.

GKOS had negative earnings in each of the past 5 years.

GKOS had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -15.02%, GKOS is in line with its industry, outperforming 55.03% of the companies in the same industry.

GKOS has a better Return On Equity (-19.09%) than 62.43% of its industry peers.

		Industry Rank	Sector Rank
ROA	-15.02%
ROE	-19.09%
ROIC	N/A

ROA(3y)-13.08%

ROA(5y)-11.18%

ROE(3y)-22.32%

ROE(5y)-18.69%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

GKOS has a Gross Margin of 75.48%. This is amongst the best in the industry. GKOS outperforms 87.83% of its industry peers.

In the last couple of years the Gross Margin of GKOS has declined.

The Profit Margin and Operating Margin are not available for GKOS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	75.48%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.81%

GM growth 5Y-2.05%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GKOS does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for GKOS has been increased compared to 1 year ago.

The number of shares outstanding for GKOS has been increased compared to 5 years ago.

GKOS has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 14.95 indicates that GKOS is not in any danger for bankruptcy at the moment.

GKOS has a Altman-Z score of 14.95. This is amongst the best in the industry. GKOS outperforms 94.18% of its industry peers.

GKOS has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.

GKOS has a Debt to Equity ratio of 0.09. This is in the better half of the industry: GKOS outperforms 60.32% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	N/A
Altman-Z	14.95

ROIC/WACCN/A

WACC8.65%

2.3 Liquidity

A Current Ratio of 5.99 indicates that GKOS has no problem at all paying its short term obligations.

GKOS's Current ratio of 5.99 is amongst the best of the industry. GKOS outperforms 82.54% of its industry peers.

GKOS has a Quick Ratio of 5.22. This indicates that GKOS is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 5.22, GKOS belongs to the top of the industry, outperforming 80.95% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	5.99
Quick Ratio	5.22

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.34% over the past year.

GKOS shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.85%.

The Revenue has been growing by 10.10% on average over the past years. This is quite good.

EPS 1Y (TTM)40.34%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%68.57%

Revenue 1Y (TTM)21.85%

Revenue growth 3Y9.26%

Revenue growth 5Y10.1%

Sales Q2Q%24.57%

3.2 Future

Based on estimates for the next years, GKOS will show a very strong growth in Earnings Per Share. The EPS will grow by 32.87% on average per year.

The Revenue is expected to grow by 31.98% on average over the next years. This is a very strong growth

EPS Next Y47.44%

EPS Next 2Y39.84%

EPS Next 3Y35.7%

EPS Next 5Y32.87%

Revenue Next Year26.9%

Revenue Next 2Y27.39%

Revenue Next 3Y27.24%

Revenue Next 5Y31.98%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GKOS. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GKOS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

GKOS's earnings are expected to grow with 35.70% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y39.84%

EPS Next 3Y35.7%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

GKOS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GLAUKOS CORP

NYSE:GKOS (4/30/2025, 8:10:00 PM)

After market: 88 -6.25 (-6.63%)

94.25

+0.42 (+0.45%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)04-30 2025-04-30/amc

Earnings (Next)07-29 2025-07-29/amc

Inst Owners104.83%

Inst Owner Change0.05%

Ins Owners3.22%

Ins Owner Change1.5%

Market Cap5.38B

Analysts83.81

Price Target157.39 (66.99%)

Short Float %5.74%

Short Ratio2.88

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)20.13%

Min EPS beat(2)-2.27%

Max EPS beat(2)42.53%

EPS beat(4)2

Avg EPS beat(4)5.44%

Min EPS beat(4)-19.53%

Max EPS beat(4)42.53%

EPS beat(8)4

Avg EPS beat(8)2.78%

EPS beat(12)7

Avg EPS beat(12)-1.43%

EPS beat(16)11

Avg EPS beat(16)4.94%

Revenue beat(2)2

Avg Revenue beat(2)3.14%

Min Revenue beat(2)2.69%

Max Revenue beat(2)3.59%

Revenue beat(4)4

Avg Revenue beat(4)4.32%

Min Revenue beat(4)2.69%

Max Revenue beat(4)5.53%

Revenue beat(8)8

Avg Revenue beat(8)4.19%

Revenue beat(12)12

Avg Revenue beat(12)4.4%

Revenue beat(16)15

Avg Revenue beat(16)4.2%

PT rev (1m)-8.44%

PT rev (3m)-0.45%

EPS NQ rev (1m)0%

EPS NQ rev (3m)8.6%

EPS NY rev (1m)0.94%

EPS NY rev (3m)10.48%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-2.4%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0.17%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	14.03
P/FCF	N/A
P/OCF	N/A
P/B	7.02
P/tB	12.3
EV/EBITDA	N/A

EPS(TTM)-1.42

EYN/A

EPS(NY)-0.08

Fwd EYN/A

FCF(TTM)-1.18

FCFYN/A

OCF(TTM)-1.07

OCFYN/A

SpS6.72

BVpS13.43

TBVpS7.66

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-15.02%
ROE	-19.09%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	75.48%
FCFM	N/A

ROA(3y)-13.08%

ROA(5y)-11.18%

ROE(3y)-22.32%

ROE(5y)-18.69%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.81%

GM growth 5Y-2.05%

F-Score4

Asset Turnover0.39

Health

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	17.67%
Cap/Sales	1.64%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.99
Quick Ratio	5.22
Altman-Z	14.95

F-Score4

WACC8.65%

ROIC/WACCN/A

Cap/Depr(3y)57.91%

Cap/Depr(5y)71.69%

Cap/Sales(3y)6.26%

Cap/Sales(5y)7.62%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)40.34%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%68.57%

EPS Next Y47.44%

EPS Next 2Y39.84%

EPS Next 3Y35.7%

EPS Next 5Y32.87%

Revenue 1Y (TTM)21.85%

Revenue growth 3Y9.26%

Revenue growth 5Y10.1%

Sales Q2Q%24.57%

Revenue Next Year26.9%

Revenue Next 2Y27.39%

Revenue Next 3Y27.24%

Revenue Next 5Y31.98%

EBIT growth 1Y14.65%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year66.98%

EBIT Next 3Y47.42%

EBIT Next 5Y43.81%

FCF growth 1Y13.32%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-6.16%

OCF growth 3YN/A

OCF growth 5YN/A

GLAUKOS CORP (GKOS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens